The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC).
Hagen F. Kennecke
Honoraria - Amgen; Bristol-Myers Squibb; Roche; Sanofi
Research Funding - Amgen; Bristol-Myers Squibb
Leo Chen
No relevant relationships to disclose
C. D. Blanke
No relevant relationships to disclose
Winson Y. Cheung
No relevant relationships to disclose
Kimberly Schaff
No relevant relationships to disclose
Caroline Speers
No relevant relationships to disclose